Loading…

Is there any association between insulin resistance and thyroid cancer? : a case control study

Insulin stimulates proliferation of thyroid cells in culture. The presence of insulin resistance (IR) is associated with larger thyroid gland volume and an increased prevalence of thyroid nodules. The aim of this study was to investigate the presence of any possible association between IR and thyroi...

Full description

Saved in:
Bibliographic Details
Published in:Endocrine 2014-02, Vol.45 (1), p.55-60
Main Authors: Balkan, Fevzi, Onal, Eda Demir, Usluogullari, Alper, Tuzun, Dilek, Ozdemir, Didem, Inancli, Serap Soytac, Ersoy, Reyhan, Cakir, Bekir
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c344t-4b24577a336864da361871ae9eabc98bab5b7886a9ce144ffb1007236068e96b3
cites cdi_FETCH-LOGICAL-c344t-4b24577a336864da361871ae9eabc98bab5b7886a9ce144ffb1007236068e96b3
container_end_page 60
container_issue 1
container_start_page 55
container_title Endocrine
container_volume 45
creator Balkan, Fevzi
Onal, Eda Demir
Usluogullari, Alper
Tuzun, Dilek
Ozdemir, Didem
Inancli, Serap Soytac
Ersoy, Reyhan
Cakir, Bekir
description Insulin stimulates proliferation of thyroid cells in culture. The presence of insulin resistance (IR) is associated with larger thyroid gland volume and an increased prevalence of thyroid nodules. The aim of this study was to investigate the presence of any possible association between IR and thyroid cancer. Forty-one patients with diffuse thyroid cancer (Group 1) were matched for age and gender with 41 patients with nodular goiter (Group 2). Both groups were compared in terms of frequency of IR, as estimated by the homeostasis model assessment, as well as other parameters of the metabolic syndrome (MetS). Fourteen patients (34.1 %) in each group had MetS. Twelve patients (29.3 %) in group 1 had IR compared to 10 (24.4 %) in group 2. Mean HOMA-IR scores in group 1 and 2 were 2.5 ± 2.2 and 1.8 ± 1.1, respectively. Thirty-two patients (78 %) in group 1 had a body mass index (BMI) of more than 25 compared to 33 patients (80.5 %) in group 2. The difference between groups with regard to HOMA-IR, the frequency of IR, BMI, and any of the parameters of MetS was statistically insignificant ( p  > 0.05). A subgroup analysis based on tumor size did not reveal a significant difference between patients with microcarcinoma (≤10 mm) and macrocarcinoma (>10 mm) in terms of any of the study parameters ( p  > 0.05). Neither MetS nor IR was a significant risk factor for thyroid cancer following logistic regression analysis ( p  > 0.05). IR is not more prevalent in patients with thyroid cancer. Some other pathologic mechanisms may be more prominent during thyroid carcinogenesis.
doi_str_mv 10.1007/s12020-013-9942-x
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_s12020_013_9942_x</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>23564559</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-4b24577a336864da361871ae9eabc98bab5b7886a9ce144ffb1007236068e96b3</originalsourceid><addsrcrecordid>eNp9kM1KxDAUhYMozjj6AG4kL1DNf1s3IuLPwIAbBVeGJE21w0w65LY4fXtTqi5d3cu53zlwD0LnlFxSQvIroIwwkhHKs7IULNsfoDmVskwKIYdp51JmhBRvM3QCsCaEMabyYzRjXCqRwDl6XwLuPn302IQBG4DWNaZr2oCt7768D7gJ0G-agKOHBjoT3IhWyTTEtqmwG5V4g6-xSTt47NrQxXaDoeur4RQd1WYD_uxnLtDrw_3L3VO2en5c3t2uMseF6DJhmZB5bjhXhRKV4YoWOTW-9Ma6srDGSpsXhTKl81SIurbj_4wrogpfKssXiE65LrYA0dd6F5utiYOmRI-snrrSqSs9dqX3yXMxeXa93frqz_FbTgLYBEA6hQ8f9brtY0h__JP6DcBmdaI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Is there any association between insulin resistance and thyroid cancer? : a case control study</title><source>Springer Link</source><creator>Balkan, Fevzi ; Onal, Eda Demir ; Usluogullari, Alper ; Tuzun, Dilek ; Ozdemir, Didem ; Inancli, Serap Soytac ; Ersoy, Reyhan ; Cakir, Bekir</creator><creatorcontrib>Balkan, Fevzi ; Onal, Eda Demir ; Usluogullari, Alper ; Tuzun, Dilek ; Ozdemir, Didem ; Inancli, Serap Soytac ; Ersoy, Reyhan ; Cakir, Bekir</creatorcontrib><description>Insulin stimulates proliferation of thyroid cells in culture. The presence of insulin resistance (IR) is associated with larger thyroid gland volume and an increased prevalence of thyroid nodules. The aim of this study was to investigate the presence of any possible association between IR and thyroid cancer. Forty-one patients with diffuse thyroid cancer (Group 1) were matched for age and gender with 41 patients with nodular goiter (Group 2). Both groups were compared in terms of frequency of IR, as estimated by the homeostasis model assessment, as well as other parameters of the metabolic syndrome (MetS). Fourteen patients (34.1 %) in each group had MetS. Twelve patients (29.3 %) in group 1 had IR compared to 10 (24.4 %) in group 2. Mean HOMA-IR scores in group 1 and 2 were 2.5 ± 2.2 and 1.8 ± 1.1, respectively. Thirty-two patients (78 %) in group 1 had a body mass index (BMI) of more than 25 compared to 33 patients (80.5 %) in group 2. The difference between groups with regard to HOMA-IR, the frequency of IR, BMI, and any of the parameters of MetS was statistically insignificant ( p  &gt; 0.05). A subgroup analysis based on tumor size did not reveal a significant difference between patients with microcarcinoma (≤10 mm) and macrocarcinoma (&gt;10 mm) in terms of any of the study parameters ( p  &gt; 0.05). Neither MetS nor IR was a significant risk factor for thyroid cancer following logistic regression analysis ( p  &gt; 0.05). IR is not more prevalent in patients with thyroid cancer. Some other pathologic mechanisms may be more prominent during thyroid carcinogenesis.</description><identifier>ISSN: 1355-008X</identifier><identifier>EISSN: 1559-0100</identifier><identifier>DOI: 10.1007/s12020-013-9942-x</identifier><identifier>PMID: 23564559</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adolescent ; Adult ; Aged ; Case-Control Studies ; Diabetes ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - epidemiology ; Endocrinology ; Female ; Humanities and Social Sciences ; Humans ; Hyperplasia - epidemiology ; Insulin Resistance - physiology ; Internal Medicine ; Male ; Medicine ; Medicine &amp; Public Health ; Metabolic Syndrome - complications ; Metabolic Syndrome - epidemiology ; Middle Aged ; multidisciplinary ; Original Article ; Risk Factors ; Science ; Thyroid Gland - pathology ; Thyroid Neoplasms - epidemiology ; Thyroid Neoplasms - etiology ; Thyroid Nodule - epidemiology ; Thyroid Nodule - pathology ; Young Adult</subject><ispartof>Endocrine, 2014-02, Vol.45 (1), p.55-60</ispartof><rights>Springer Science+Business Media New York 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-4b24577a336864da361871ae9eabc98bab5b7886a9ce144ffb1007236068e96b3</citedby><cites>FETCH-LOGICAL-c344t-4b24577a336864da361871ae9eabc98bab5b7886a9ce144ffb1007236068e96b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23564559$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Balkan, Fevzi</creatorcontrib><creatorcontrib>Onal, Eda Demir</creatorcontrib><creatorcontrib>Usluogullari, Alper</creatorcontrib><creatorcontrib>Tuzun, Dilek</creatorcontrib><creatorcontrib>Ozdemir, Didem</creatorcontrib><creatorcontrib>Inancli, Serap Soytac</creatorcontrib><creatorcontrib>Ersoy, Reyhan</creatorcontrib><creatorcontrib>Cakir, Bekir</creatorcontrib><title>Is there any association between insulin resistance and thyroid cancer? : a case control study</title><title>Endocrine</title><addtitle>Endocrine</addtitle><addtitle>Endocrine</addtitle><description>Insulin stimulates proliferation of thyroid cells in culture. The presence of insulin resistance (IR) is associated with larger thyroid gland volume and an increased prevalence of thyroid nodules. The aim of this study was to investigate the presence of any possible association between IR and thyroid cancer. Forty-one patients with diffuse thyroid cancer (Group 1) were matched for age and gender with 41 patients with nodular goiter (Group 2). Both groups were compared in terms of frequency of IR, as estimated by the homeostasis model assessment, as well as other parameters of the metabolic syndrome (MetS). Fourteen patients (34.1 %) in each group had MetS. Twelve patients (29.3 %) in group 1 had IR compared to 10 (24.4 %) in group 2. Mean HOMA-IR scores in group 1 and 2 were 2.5 ± 2.2 and 1.8 ± 1.1, respectively. Thirty-two patients (78 %) in group 1 had a body mass index (BMI) of more than 25 compared to 33 patients (80.5 %) in group 2. The difference between groups with regard to HOMA-IR, the frequency of IR, BMI, and any of the parameters of MetS was statistically insignificant ( p  &gt; 0.05). A subgroup analysis based on tumor size did not reveal a significant difference between patients with microcarcinoma (≤10 mm) and macrocarcinoma (&gt;10 mm) in terms of any of the study parameters ( p  &gt; 0.05). Neither MetS nor IR was a significant risk factor for thyroid cancer following logistic regression analysis ( p  &gt; 0.05). IR is not more prevalent in patients with thyroid cancer. Some other pathologic mechanisms may be more prominent during thyroid carcinogenesis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Case-Control Studies</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - epidemiology</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Hyperplasia - epidemiology</subject><subject>Insulin Resistance - physiology</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metabolic Syndrome - complications</subject><subject>Metabolic Syndrome - epidemiology</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Original Article</subject><subject>Risk Factors</subject><subject>Science</subject><subject>Thyroid Gland - pathology</subject><subject>Thyroid Neoplasms - epidemiology</subject><subject>Thyroid Neoplasms - etiology</subject><subject>Thyroid Nodule - epidemiology</subject><subject>Thyroid Nodule - pathology</subject><subject>Young Adult</subject><issn>1355-008X</issn><issn>1559-0100</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp9kM1KxDAUhYMozjj6AG4kL1DNf1s3IuLPwIAbBVeGJE21w0w65LY4fXtTqi5d3cu53zlwD0LnlFxSQvIroIwwkhHKs7IULNsfoDmVskwKIYdp51JmhBRvM3QCsCaEMabyYzRjXCqRwDl6XwLuPn302IQBG4DWNaZr2oCt7768D7gJ0G-agKOHBjoT3IhWyTTEtqmwG5V4g6-xSTt47NrQxXaDoeur4RQd1WYD_uxnLtDrw_3L3VO2en5c3t2uMseF6DJhmZB5bjhXhRKV4YoWOTW-9Ma6srDGSpsXhTKl81SIurbj_4wrogpfKssXiE65LrYA0dd6F5utiYOmRI-snrrSqSs9dqX3yXMxeXa93frqz_FbTgLYBEA6hQ8f9brtY0h__JP6DcBmdaI</recordid><startdate>20140201</startdate><enddate>20140201</enddate><creator>Balkan, Fevzi</creator><creator>Onal, Eda Demir</creator><creator>Usluogullari, Alper</creator><creator>Tuzun, Dilek</creator><creator>Ozdemir, Didem</creator><creator>Inancli, Serap Soytac</creator><creator>Ersoy, Reyhan</creator><creator>Cakir, Bekir</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20140201</creationdate><title>Is there any association between insulin resistance and thyroid cancer? : a case control study</title><author>Balkan, Fevzi ; Onal, Eda Demir ; Usluogullari, Alper ; Tuzun, Dilek ; Ozdemir, Didem ; Inancli, Serap Soytac ; Ersoy, Reyhan ; Cakir, Bekir</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-4b24577a336864da361871ae9eabc98bab5b7886a9ce144ffb1007236068e96b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Case-Control Studies</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - epidemiology</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Hyperplasia - epidemiology</topic><topic>Insulin Resistance - physiology</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metabolic Syndrome - complications</topic><topic>Metabolic Syndrome - epidemiology</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Original Article</topic><topic>Risk Factors</topic><topic>Science</topic><topic>Thyroid Gland - pathology</topic><topic>Thyroid Neoplasms - epidemiology</topic><topic>Thyroid Neoplasms - etiology</topic><topic>Thyroid Nodule - epidemiology</topic><topic>Thyroid Nodule - pathology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Balkan, Fevzi</creatorcontrib><creatorcontrib>Onal, Eda Demir</creatorcontrib><creatorcontrib>Usluogullari, Alper</creatorcontrib><creatorcontrib>Tuzun, Dilek</creatorcontrib><creatorcontrib>Ozdemir, Didem</creatorcontrib><creatorcontrib>Inancli, Serap Soytac</creatorcontrib><creatorcontrib>Ersoy, Reyhan</creatorcontrib><creatorcontrib>Cakir, Bekir</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Endocrine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Balkan, Fevzi</au><au>Onal, Eda Demir</au><au>Usluogullari, Alper</au><au>Tuzun, Dilek</au><au>Ozdemir, Didem</au><au>Inancli, Serap Soytac</au><au>Ersoy, Reyhan</au><au>Cakir, Bekir</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is there any association between insulin resistance and thyroid cancer? : a case control study</atitle><jtitle>Endocrine</jtitle><stitle>Endocrine</stitle><addtitle>Endocrine</addtitle><date>2014-02-01</date><risdate>2014</risdate><volume>45</volume><issue>1</issue><spage>55</spage><epage>60</epage><pages>55-60</pages><issn>1355-008X</issn><eissn>1559-0100</eissn><abstract>Insulin stimulates proliferation of thyroid cells in culture. The presence of insulin resistance (IR) is associated with larger thyroid gland volume and an increased prevalence of thyroid nodules. The aim of this study was to investigate the presence of any possible association between IR and thyroid cancer. Forty-one patients with diffuse thyroid cancer (Group 1) were matched for age and gender with 41 patients with nodular goiter (Group 2). Both groups were compared in terms of frequency of IR, as estimated by the homeostasis model assessment, as well as other parameters of the metabolic syndrome (MetS). Fourteen patients (34.1 %) in each group had MetS. Twelve patients (29.3 %) in group 1 had IR compared to 10 (24.4 %) in group 2. Mean HOMA-IR scores in group 1 and 2 were 2.5 ± 2.2 and 1.8 ± 1.1, respectively. Thirty-two patients (78 %) in group 1 had a body mass index (BMI) of more than 25 compared to 33 patients (80.5 %) in group 2. The difference between groups with regard to HOMA-IR, the frequency of IR, BMI, and any of the parameters of MetS was statistically insignificant ( p  &gt; 0.05). A subgroup analysis based on tumor size did not reveal a significant difference between patients with microcarcinoma (≤10 mm) and macrocarcinoma (&gt;10 mm) in terms of any of the study parameters ( p  &gt; 0.05). Neither MetS nor IR was a significant risk factor for thyroid cancer following logistic regression analysis ( p  &gt; 0.05). IR is not more prevalent in patients with thyroid cancer. Some other pathologic mechanisms may be more prominent during thyroid carcinogenesis.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23564559</pmid><doi>10.1007/s12020-013-9942-x</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1355-008X
ispartof Endocrine, 2014-02, Vol.45 (1), p.55-60
issn 1355-008X
1559-0100
language eng
recordid cdi_crossref_primary_10_1007_s12020_013_9942_x
source Springer Link
subjects Adolescent
Adult
Aged
Case-Control Studies
Diabetes
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - epidemiology
Endocrinology
Female
Humanities and Social Sciences
Humans
Hyperplasia - epidemiology
Insulin Resistance - physiology
Internal Medicine
Male
Medicine
Medicine & Public Health
Metabolic Syndrome - complications
Metabolic Syndrome - epidemiology
Middle Aged
multidisciplinary
Original Article
Risk Factors
Science
Thyroid Gland - pathology
Thyroid Neoplasms - epidemiology
Thyroid Neoplasms - etiology
Thyroid Nodule - epidemiology
Thyroid Nodule - pathology
Young Adult
title Is there any association between insulin resistance and thyroid cancer? : a case control study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T06%3A35%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20there%20any%20association%20between%20insulin%20resistance%20and%20thyroid%20cancer?%20:%20a%20case%20control%20study&rft.jtitle=Endocrine&rft.au=Balkan,%20Fevzi&rft.date=2014-02-01&rft.volume=45&rft.issue=1&rft.spage=55&rft.epage=60&rft.pages=55-60&rft.issn=1355-008X&rft.eissn=1559-0100&rft_id=info:doi/10.1007/s12020-013-9942-x&rft_dat=%3Cpubmed_cross%3E23564559%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c344t-4b24577a336864da361871ae9eabc98bab5b7886a9ce144ffb1007236068e96b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/23564559&rfr_iscdi=true